Overview of Acquired and Genetic Lipodystrophies

Adipose Tissue in Health and Disease

Volumn , Issue , 2010, Pages 385-402

  Joy, Tisha ^a   Hegele, Robert A ^b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b WESTERN UNIVERSITY   (Canada)

Author keywords

Acquired lipodystrophy; Familial partial lipodystrophy; Genetic lipodystrophy; Hutchinson Gilford progeria syndrome; Mandibuloacral dysplasia; Neonatal progeroid syndrome; SHORT; Werner syndrome

Indexed keywords

EID: 84885566823     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527629527.ch20     Document Type: Chapter

References (80)

1. Garg, A. (2004) Acquired and inherited lipodystrophies. N. Engl. J. Med., 350, 1220-1234.
2. Hegele, R.A. (2003) Monogenic forms of insulin resistance: apertures that expose the common metabolic syndrome. Trends Endocrinol. Metab., 14, 371-377.
3. Simha, V. and Garg, A. (2006) Lipodystrophy: lessons in lipid and energy metabolism. Curr. Opin. Lipidol., 17, 162-169.
4. Berardinelli, W. (1954) An undiagnosed endocrinometabolic syndrome: report of two cases. J. Clin. Endocrinol. Metab., 14, 193-204.
5. Seip, M. (1959) Lipodystrophy and gigantism with associated endocrine manifestations: a new diencephalic syndrome? Acta Paediatr., 48, 555-574.
6. Al-Attar, S.A., Pollex, R.L., Robinson, J.F., Miskie, B.A., Walcarius, R., Little, C.H., Rutt, B.K., and Hegele, R.A. (2007) Quantitative and qualitative differences in subcutaneous adipose tissue stores across lipodystrophy types shown by magnetic resonance imaging. BMC Med. Imaging, 7, 3.
7. Westvik, J. (1996) Radiological features in lipodystrophy. Acta Paediatr. Suppl., 413, 44-51.
8. Seip, M. and Tryqstad, O. (1996) Generalized lipodystrophy, congenital and acquired (lipoatrophy). Acta Paediatr. Suppl., 413, 2-28.
9. Fleckenstein, J.L., Garg, A., Bonte, F.J., Vuitch, M.F., and Peshock, R.M. (1992) The skeleton in congenital, generalized lipodystrophy: evaluation using wholebody radiographic surveys, magnetic resonance imaging and technetium-99m bone scintigraphy. Skeletal Radiol., 21, 381-386.
10. Agarwal, A.K., Simha, V., Oral, E.A., Moran, S.A., Gorden, P., O'Rahilly, S., Zaidi, Z., Gurakan, F. et al. (2003) Phenotypic and genetic heterogeneity in congenital generalized lipodystrophy. J. Clin. Endocrinol. Metab., 88, 4840-4847.
11. Haque, W.A., Shimomura, I., Matsuzawa, Y., and Garg, A. (2002) Serum adiponectin and leptin levels in patients with lipodystrophies. J. Clin. Endocrinol. Metab., 87, 2395-2398.
12. Agarwal, A.K. and Garg, A. (2006) Genetic basis of lipodystrophies and management of metabolic complications. Annu. Rev. Med., 57, 297-311.
13. Garg, A., Wilson, R., Barnes, R., Arioglu, E., Zaidi, Z., Gurakan, F., Kocak, N., O'Rahilly, S. et al. (1999) A gene for congenital generalized lipodystrophy maps to human chromosome 9q34. J. Clin. Endocrinol. Metab., 84, 3390-3394.
14. Agarwal, A.K., Arioglu, E., De Almeida, S., Akkoc, N., Taylor, S.I., Bowcock, A.M., Barnes, R.I., and Garg, A. (2002) AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34. Nat. Genet., 31, 21-23.
15. Agarwal, A.K. and Garg, A. (2003) Congenital generalized lipodystrophy: significance of triglyceride biosynthetic pathways. Trends Endocrinol. Metab., 14, 214-221.
16. Magre, J., Delepine, M., Khallouf, E., Gedde-Dahl, T. Jr., Van Maldergem, L., Sobel, E., Papp, J., Meier, M. et al. (2001) Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy on chromosome 11q13. Nat. Genet., 28, 365-370.
17. Lundin, C., Nordstrom, R., Wagner, K., Windpassinger, C., Andersson, H., von Heijne, G., and Nilsson, I. (2006) Membrane topology of the human seipin protein. FEBS Lett., 580, 281-2284.
18. Kobberling, J., Willms, B., Katterman, R., and Creutzfeldt, W. (1975) Lipodystrophy of the extremities: a dominantly inherited syndrome associated with lipoatrophic diabetes. Humangenetik, 29, 111-120.
19. Dunnigan, M.G., Cochrane, M.A., Kelly, A., and Scott, J.W. (1974) Familial lipoatrophic diabetes with dominant transmission: a new syndrome. Q. J. Med., 43, 33-48.
20. Kobberling, J. and Dunnigan, M.G. (1986) Familial partial lipodystrophy: two types of an X-linked dominant syndrome, lethal in the hemizygous state. J. Med. Genet., 23, 120-127.
21. Garg, A., Peshock, R.M., and Fleckenstein, J.L. (1999) Adipose tissue pattern distribution in patients with familial partial lipodystrophy (Dunnigan variety). J. Clin. Endocrinol. Metab., 84, 170-174.
22. Garg, A., Vinaitheerthan, M., Weatherall, P.T., and Bowcock, A.M. (2001) Phenotypic heterogeneity in patients with familial partial lipodystrophy (Dunnigan variety) related to the site of missense mutations in lamin A/C gene. J. Clin. Endocrinol. Metab., 86, 59-65.
23. Ludtke, A., Genschel, J., Brabant, G., Bauditz, J., Taupitz, M., Koch, M., Wermke, W., Worman, H.J. et al. (2005) Hepatic steatosis in Dunnigan-type familial partial lipodystrophy. Am. J. Gastroenterol., 100, 2218-2224.
24. Hegele, R.A. (2005) Lessons from human mutations in PPARc. Int. J. Obes., 29, S31-S35.
25. Garg, A. (2000) Gender differences in the prevalence of metabolic complications in familial partial lipodystrophy (Dunnigan variety). J. Clin. Endocrinol. Metab., 85, 1776-1782.
26. Haque, W.A., Oral, E.A., Dietz, K., Bowcock, A.M., Agarwal, A.K., and Garg, A. (2003) Risk factors for diabetes in familial partial lipodystrophy, Dunnigan variety. Diabetes Care, 26, 1350-1355.
27. Hegele, R.A. (2001) Premature atherosclerosis associated with monogenic insulin resistance. Circulation, 103, 2225-2229.
28. Vantyghem, M.C., Pigny, P., Maurage, C.A., Rouaix-Emery, N., Stojkovic, T., Cuisset, J.M., Millaire, A., Lascols, O. et al. (2004) Patients with familial partial lipodystrophy of the Dunnigan type due to a LMNA R482W mutation show muscular and cardiac abnormalities. J. Clin. Endocrinol. Metab., 89, 5337-5346.
29. Cao, H. and Hegele, R.A. (2000) Nuclear lamin A/C R482Q mutation in canadian kindreds with Dunnigan-type familial partial lipodystrophy. Hum. Mol. Genet., 9, 109-112.
30. Hegele, R. (2005) LMNA mutation position predicts organ system involvement in laminopathies. Clin. Genet., 68, 31-34.
31. Capell, B.C. and Collins, F.S. (2006) Human laminopathies: nuclei gone awry. Nature, 7, 940-952.
32. Lanktree, M., Cao, H., Rabkin, S., Hanna, A., and Hegele, R. (2007) Novel LMNA mutations seen in patients with familial partial lipodystrophy subtype 2 (FPLD2; MIM 151660). Clin. Genet., 71, 183-186.
33. Agarwal, A.K. and Garg, A. (2002) A novel heterozygous mutation in peroxisome proliferator-activated receptor-gamma gene in a patient with familial partial lipodystrophy. J. Clin. Endocrinol. Metab., 87, 408-411.
34. Agostini, M., Schoenmakers, E., Mitchell, C., Szatmari, I., Savage, D., Smith, A., Rajanayagam, O., Semple, R. et al. (2006) Non-DNA binding, dominant-negative, human PPARgamma mutations cause lipodystrophic insulin resistance. Cell Metab., 4, 303-311.
35. Al-Shali, K., Cao, H., Knoers, N.,Hermus, A.R., Tack, C.J., and Hegele, R.A. (2004) A single-base mutation in the peroxisome proliferator-activated receptor gamma4 promoter associated with altered in vitro expression and partial lipodystrophy. J. Clin. Endocrinol. Metab., 89, 5655-5660.
36. Francis, G.A., Li, G., Casey, R., Wang, J., Cao, H., Leff, T., and Hegele, R.A. (2006) Peroxisomal proliferator activated receptor-gamma deficiency in a Canadian kindred with familial partial lipodystrophy type 3 (FPLD3). BMC Med. Genet., 7, 3.
37. Hegele, R.A., Cao, H., Frankowski, C., Mathews, S.T., and Leff, T. (2002) PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy. Diabetes, 51, 3586-3590.
38. Hegele, R.A., Ur, E., Ransom, T.P., and Cao, H. (2006) A frameshift mutation in peroxisome-proliferator-activated receptor-gamma in familial partial lipodystrophy subtype 3 (FPLD3; MIM 604367). Clin. Genet., 70, 360-362.
39. Li, G. and Leff, T. (2007) Altered promoter recycling rates contribute to dominantnegative activity of human peroxisome proliferator-activated receptor gamma mutations associated with diabetes. Mol. Endocrinol., 21, 857-864.
40. Monajemi, H., Zhang, L., Li, G., Jeninga, E.H., Cao, H., Maas, M., Brouwer, C.B., Kalkhoven, E. et al. (2007) Familial partial lipodystrophy phenotype resulting from a single-base mutation in DNA binding domain of peroxisome proliferatoractivated receptor gamma. J. Clin. Endocrinol. Metab., 92, 1606-1512.
41. Savage, D.B., Tan, G.D., Acerini, C.L., Jebb, S.A., Agostini, M., Gurnell, M., Williams, R.L., Umpleby, A.M. et al. (2003) Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferatoractivated receptor-gamma. Diabetes, 52, 910-917.
42. Sharma, A.M. and Staels, B. (2007) Review: peroxisome proliferator-activated receptor gamma and adipose tissue - understanding obesity-related changes in regulation of lipid and glucose metabolism. J. Clin. Endocrinol.Metab., 92, 386-395.
43. Misra, A. and Garg, A. (2003) Clinical features and metabolic derangements in acquired generalized lipodystrophy: case reports and review of the literature. Medicine, 82, 129-146.
44. Mitchell, S.W. (1885) Singular case of absence of adipose tissue matter in the upper half of the body. Am. J.Med. Sci., 90, 105-106.
45. Barraquer, L. (1907) Histoire clinique d'un cas d'atrophie du tissue celluloadipeux. Neurolog. Zentralblatt, 26, 1072.
46. Simons, A. (1911) Lipodystrophia progressive. Z. Ges. Neurol. Psychiat., 5, 29-38.
47. Misra, A. and Garg, A. (2004) Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: report of 35 cases and review of the literature. Medicine, 83, 18-34.
48. Hegele, R.A., Cao, H., Liu, D.M., Costain, G.A., Charlton-Menys, V., Rodger, N.W., and Durrington, P.N. (2006) Sequencing of the reannotated LMNB2 gene reveals novel mutations in patients with acquired partial lipodystrophy. Am. J. Hum. Genet., 79, 383-389.
49. Chen, D., Misra, A., and Garg, A. (2002) Lipodystrophy in human immunodeficiency virus-infected patients. J. Clin. Endocrinol. Metab., 87, 4845-4856.
50. Lo, J.C., Mulligan, K., Tai, V.W., Algren, H., and Schambelan, M. (1998) Buffalo hump in men with HIV-1 infection. Lancet, 351, 867-870.
51. Miller, K.K., Daly, P., Sentochnik, D., Doweiko, J., Samore, M., Basgoz, N.O., and Grinspoon, S.K. (1998) Pseudo-Cushing's syndrome in human immunodeficiency virus-infected patients. Clin. Infect. Dis., 27, 68-72.
52. Roth, V., Kravcik, S., and Angel, J. (1998) Development of cervical fat pads following therapy with human immunodeficiency virus type 1 protease inhibitors. Clin. Infect. Dis., 27, 65-67.
53. FRAM Investigators (2006) Fat distribution in women with HIV infection. J. Acquir. Immune Defic. Syndr., 42, 562-571.
54. Bacchetti, P., Gripshover, B., Grunfeld, C., Heymsfield, S., McCreath, H., Osmond, D., Saag, M., Scherzer, R. et al. (2005) Study of fat redistribution and metabolic change in HIV infection (FRAM). Fat distribution in men with HIV infection. J. Acquir. Immune Defic. Syndr., 40, 121-131.
55. Tien, P.C., Cole, S.R., Williams, C.M., Li, R., Justman, J.E., Cohen, M.H., Young, M., Rubin, N. et al. (2003) Incidence of lipoatrophy and lipohypertrophy in the women's interagency HIVstudy. J. Acquir. Immune Defic. Syndr., 34, 461-466.
56. Grinspoon, S. and Carr, A. (2005) Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N. Engl. J. Med., 352, 48-62.
57. Grinspoon, S. (2005) Androgen deficiency and HIV infection. Clin. Infect. Dis., 41, 1804-1805.
58. Ristig, M., Drechsler, H., and Powderly, W.G. (2005) Hepatic steatosis and HIV infection. AIDS Patient Care STDs, 19, 356-365.
59. Johnsen, S., Dolan, S.E., Fitch, K.V., Killilea, K.M., Schifren, J.L., and Grinspoon, S.K. (2005) Absence of polycystic ovary syndrome features in human immunodeficiency virus-infected women despite significant hyperinsulinemia and truncal adiposity. J. Clin. Endocrinol. Metab., 90, 5596-5604.
60. Mynarcik, D.C., Combs, T., McNurlan, M.A., Scherer, P.E., Komaroff, E., and Gelato, M.C. (2002) Adiponectin and leptin levels in HIV-infected subjects with insulin resistance and body fat redistribution. J. Acquir. Immune Defic. Syndr., 31, 514-520.
61. Kosmiski, L., Kuritzkes, D., Lichtenstein, K., and Eckel, R. (2003) Adipocyte-derived hormone levels in HIV lipodystrophy. Antivir. Ther., 8, 9-15.
62. Simha, V. and Garg, A. (2002) Body fat distribution and metabolic derangements in patients with familial partial lipodystrophy associated with mandibuloacral dysplasia. J. Clin. Endocrinol. Metab., 87, 776-785.
63. Cutler, D.L., Kaufmann, S., and Friedenberg, G.R. (1991) Insulin-resistant diabetes mellitus and hypermetabolism in mandibuloacral dysplasia: a newly recognized form of partial lipodystrophy. J. Clin. Endocrinol. Metab., 73, 1056-1061.
64. Novelli, G., Muchir, A., Sangiuolo, F., Helbling-Leclerc, A., D'Apice, M.R., Massart, C., Capon, F., Sbraccia, P. et al. (2002) Mandibuloacral dysplasia is caused by a mutation in LMNA-encoding lamin A/C. Am. J. Hum. Genet., 71, 426-431.
65. Shen, J.J., Brown, C.A., Lupski, J.R., and Potocki, L. (2003) Mandibuloacral dysplasia caused by homozygosity for the R527H mutation in lamin A/C. J. Med. Genet., 40, 854-857.
66. Simha, V., Agarwal, A.K., Oral, E.A., Fryns, J.P., and Garg, A. (2003) Genetic and phenotypic heterogeneity in patients with mandibuloacral dysplasia-associated lipodystrophy. J. Clin. Endocrinol. Metab., 88, 2821-2824.
67. Garg, A., Cogulu, O., Ozkinay, F., Onay, H., and Agarwal, A.K. (2005) A novel homozygous Ala529Val LMNA mutation in Turkish patients with mandibuloacral dysplasia. J. Clin. Endocrinol. Metab., 90, 5259-5264.
68. Agarwal, A.K., Fryns, J.P., Auchus, R.J., and Garg, A. (2003) Zinc metalloproteinase, ZMPSTE24, is mutated in mandibuloacral dysplasia. Hum. Mol. Genet., 12, 1995-2001.
69. Agarwal, A.K., Zhou, X.J., Hall, R.K., Nicholls, K., Bankier, A., Van Esch, H., Fryns, J.P., and Garg, A. (2006) Focal segmental glomerulosclerosis in patients with mandibuloacral dysplasia owing to ZMPSTE24 deficiency. J. Invest. Med., 54, 208-213.
70. Gorlin, R.J., Cervenka, J., Moller, K., Horrobin, M., and Witkop, C.J. Jr. (1975) Rieger anomaly and growth retardation (the S-H-O-R-T syndrome). Birth Defects Orig. Artic. Ser., 11, 46-48.
71. Sorge, G., Ruggieri, M., Polizzi, A., Scuderi, A., and DiPietro, M. (1996) SHORT syndrome: a new case with probable autosomal dominant inheritance. Am. J. Med. Genet., 61, 178-181.
72. Aarskog, D., Ose, L., Pande, H., and Eide, N. (1983) Autosomal dominant partial lipodystrophy associated with Rieger anomaly, short stature, and insulinopenic diabetes. Am. J. Med. Genet., 15, 29-38.
73. Pivnick, E.K., Angle, B., Kaufman, R.A., Hall, B.D., Pitukcheewanont, P., Hersh, J.H., Fowlkes, J.L., Sanders, L.P. et al. (2000) Neonatal progeroid (Wiedemann-Rautenstrauch) syndrome: report of five new cases and review. Am. J. Med. Genet., 90, 131-140.
74. Hennekam, R.C.M. (2006) Hutchinson-Gilford progeria syndrome: review of the phenotype. Am. J. Med. Genet., 140A, 2603-2624.
75. Eriksson, M., Brown, W.T., Gordon, L.B., Glynn, M.W., Singer, J., Scott, L., Erdos, M.R., Robbins, C.M. et al. (2003) Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature, 423, 293-298.
76. De Sandre-Giovannoli, A., Bernard, R., Cau, P., Navarro, C., Amiel, J., Boccaccio, I., Lyonnet, S., Stewart, C.L. et al. (2003) Lamin A truncation in Hutchinson-Gilford progeria. Science, 300, 2055.
77. Cao, H. and Hegele, R.A. (2003) LMNA is mutated in Hutchinson-Gilford progeria (MIM 176670) but not in Wiedemann-Rautenstrauch progeroid syndrome (MIM 264090). J. Hum. Genet., 48, 271-274.
78. Lebel, M. (2001) Werner syndrome: genetic and molecular basis of a premature aging disorder. Cell. Mol. Life Sci., 58, 857-867.
79. Hoepffner, H.-J., Dreyer, M., Reimers, U., Schmidt-Preuss, U., Koepp, H.-P., and Rudiger, H.W. (1989) A new family syndrome with impaired function of three related peptide growth factors. Hum. Genet., 83, 209-216.
80. Navarro, C.L., Cao, P., and Levy, N. (2006) Molecular bases of progeroid syndromes. Hum. Mol. Genet., 15, R151-R161.